Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults
NCT02233816Phase 2Completed
- Sponsor
- Medicago Inc.
- Start
- Jul 2014
- Primary completion
- Jun 2015
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in influenza (4 arms), sponsored by Medicago Inc. Primary endpoints: Immunogenicity (against vaccine strains) at 21 days and Safety at 21 days. Started Jul 2014; status: completed.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT02233816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02233816.